<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Ma L</submitter><funding>Ministry of Science and Technology of the People’s Republic of China</funding><funding>Strategic Priority Research Program of the Chinese Academy of Sciences</funding><funding>National Natural Science Foundation of China</funding><pagination>1385-1400</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9225223</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>18(6)</volume><pubmed_abstract>Macrophages rapidly undergo glycolytic reprogramming in response to macroautophagy/autophagy, inflammasome activation and pyroptosis for the clearance of bacteria. Identification the key molecules involved in these three events will provide critical potential therapeutic applications. Upon &lt;i>S. typhimurium&lt;/i> infection, FLT4/VEGFR3 and its ligand VEGFC were inducibly expressed in macrophages, and FLT4 signaling inhibited CASP1 (caspase 1)-dependent inflammasome activation and pyroptosis but enhanced MAP1LC3/LC3 activation for elimination of the bacteria. Consistently, FLT4 mutants lacking the extracellular ligand-binding domain increased production of the proinflammatory metabolites such as succinate and lactate, and reduced antimicrobial metabolites including citrate and NAD(P)H in macr</pubmed_abstract><journal>Autophagy</journal><pubmed_title>FLT4/VEGFR3 activates AMPK to coordinate glycometabolic reprogramming with autophagy and inflammasome activation for bacterial elimination.</pubmed_title><pmcid>PMC9225223</pmcid><funding_grant_id>2016YFC0905902</funding_grant_id><funding_grant_id>2016YFC0905900</funding_grant_id><funding_grant_id>2016YFD0500407</funding_grant_id><funding_grant_id>81930038</funding_grant_id><funding_grant_id>2016YFD0500207</funding_grant_id><funding_grant_id>2018YFA0800702</funding_grant_id><funding_grant_id>30671038</funding_grant_id><funding_grant_id>81630043</funding_grant_id><funding_grant_id>81801575</funding_grant_id><funding_grant_id>81671572</funding_grant_id><funding_grant_id>81701569</funding_grant_id><funding_grant_id>31700781</funding_grant_id><funding_grant_id>81825011</funding_grant_id><funding_grant_id>XDB19000000</funding_grant_id><funding_grant_id>81961160738</funding_grant_id><funding_grant_id>81571552</funding_grant_id><pubmed_authors>Qi L</pubmed_authors><pubmed_authors>Ma L</pubmed_authors><pubmed_authors>Wei B</pubmed_authors><pubmed_authors>Lu Y</pubmed_authors><pubmed_authors>Zhang L</pubmed_authors><pubmed_authors>Wang H</pubmed_authors><pubmed_authors>Yu H</pubmed_authors><pubmed_authors>Li N</pubmed_authors><pubmed_authors>Li W</pubmed_authors><pubmed_authors>He Y</pubmed_authors><pubmed_authors>Zhang Y</pubmed_authors><pubmed_authors>Zhao Q</pubmed_authors><pubmed_authors>Zhou F</pubmed_authors><pubmed_authors>Wu Y</pubmed_authors></additional><is_claimable>false</is_claimable><name>FLT4/VEGFR3 activates AMPK to coordinate glycometabolic reprogramming with autophagy and inflammasome activation for bacterial elimination.</name><description>Macrophages rapidly undergo glycolytic reprogramming in response to macroautophagy/autophagy, inflammasome activation and pyroptosis for the clearance of bacteria. Identification the key molecules involved in these three events will provide critical potential therapeutic applications. Upon &lt;i>S. typhimurium&lt;/i> infection, FLT4/VEGFR3 and its ligand VEGFC were inducibly expressed in macrophages, and FLT4 signaling inhibited CASP1 (caspase 1)-dependent inflammasome activation and pyroptosis but enhanced MAP1LC3/LC3 activation for elimination of the bacteria. Consistently, FLT4 mutants lacking the extracellular ligand-binding domain increased production of the proinflammatory metabolites such as succinate and lactate, and reduced antimicrobial metabolites including citrate and NAD(P)H in macr</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Jun</publication><modification>2025-04-22T08:00:26.201Z</modification><creation>2025-04-05T22:20:43.037Z</creation></dates><accession>S-EPMC9225223</accession><cross_references><pubmed>34632918</pubmed><doi>10.1080/15548627.2021.1985338</doi></cross_references></HashMap>